#Covovax production

[reportwire]

SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021, and of the total stock available at that time, around 100 million doses had already got expired. Speaking to reporters on the sidelines of the annual general meeting of Developing Countries Vaccine Manufacturers…

[allthebrazilianpolitics]

Indian lab files for clearance in Brazil of covid-19 vax

Brazil's National Health Surveillance Agency (Anvisa) has announced it had received this week the request for registration of a COVID-19 vaccine that uses recombinant protein technology.

The application has been submitted by Zalika Farmacêutica Ltda., the local representatives in Brazil of India's Serum Institute, the developers of the Covovax drug, which is intended for people over 18 years of age.

”The protocol was received on Wednesday (April 27) and is already being evaluated by the technical areas involved. The deadline for the Agency's analysis is 60 days,” Anvisa said Friday in a statement.

According to Oswaldo Cruz Foundation (FioCruz) sources quoted by Agencia Brasil, recombinant vaccines use the technology of a non-replicating viral vector of chimpanzee adenovirus. The genome is genetically manipulated so that it can no longer replicate and then they insert the SARS-CoV-2 spike protein gene. Once obtained, the adenoviruses are amplified in large numbers using modified cells to allow amplification of the adenovirus and production of the vaccine in disposable bioreactors. These adenoviruses are purified, concentrated, and stabilized to make up the final vaccine. The vaccine goes through rigorous quality control before being sent to health clinics.

Continue reading.

[jetsoday]

[香港旅遊優惠]【日本開關】2022年日本自由行懶人包 一文睇清最新入境文件、日本認可疫苗名單及MySOS申報教學

[香港旅遊優惠]【日本開關】2022年日本自由行懶人包 一文睇清最新入境文件、日本認可疫苗名單及MySOS申報教學 https://www.jetsoday.com/%e9%a6%99%e6%b8%af%e6%97%85%e9%81%8a%e5%84%aa%e6%83%a0%e3%80%90%e6%97%a5%e6%9c%ac%e9%96%8b%e9%97%9c%e3%80%912022%e5%b9%b4%e6%97%a5%e6%9c%ac%e8%87%aa%e7%94%b1%e8%a1%8c%e6%87%b6%e4%ba%ba%e5%8c%85.html 日本已於10月11日起開放自由行。疫後去旅行一切感覺都好陌生，除咗新增MySOS App申報，另外亦要預備入境所需文件同搶平機票酒店。趁日本開關，Flyday一次整理2022年日本自由行懶人包，為大家疫後日本旅行做好準備。 ▼日本開關懶人包 日本入境所需文件 疫後旅行要準備針紙或PCR陰性檢測證明，出發前帶齊以下文件： 特區護照 (建議至少有6個月有效期) 香港身份證 日本認可之疫苗接種證明書 出發前72小時內PCR檢驗新冠病毒陰性證明（適用於未打齊3針之人士） 完成MYSOS APP文件上傳程序 【唱外幣攻略】六大方法！如何最便宜兌換外幣？ 日本認可疫苗名單 入境人士於接種疫苗後至少14天方被視為已完全接種疫苗，根據厚生勞動省最新名單上共11款認可疫苗。入境日本曾接種接上「任何3劑認可疫苗」均可豁免進行核酸檢測，意指曾「溝針」，如科興＋復必泰合共3劑亦為合資格。 最新認可疫苗名單如下： 輝瑞 (復必泰) 阿斯利康 (AstraZeneca) 莫德納 (Moderna) 強生 (Johnson & Johnson) 印度巴拉特 (Bharat Biotech) 諾瓦瓦克斯 (Novavax) 科興疫苗 (Sinovac) 印度血清研究所Covishield疫苗 印度血清研究所COVOVAX疫苗 國藥中生 (北京) (Sinopharm/Beijing Institute of Biological Products) 康希諾生物腺病毒載體疫苗 (CanSinoBIO

[techminsolutions]

Hopeful of launching Covovax for adults in October this year: Serum CEO

Hopeful of launching Covovax for adults in October this year: Serum CEO

Serum Institute of India CEO Adar Poonawalla on Friday said he is hopeful that Covovax, another COVID-19 vaccine being manufactured by his company in India, will be launched in October for adults and for children by the first quarter of 2022. He also thanked the government for all the support provided to Serum Institute and said the company is always trying to expand its Covishield production…

[moneycafe]

Serum Institute starts Covovax production; govt expects 200 mn doses by Dec

Serum Institute starts Covovax production; govt expects 200 mn doses by Dec

Serum Institute of India (SII) said on Friday that production of the first batch of Covovax, the Covid-19 vaccine developed by US-based Novavax, has started in Pune. The Centre expects 200 million doses of Covovax to be available between August and December. India will allow entry of this vaccine once the USFDA approves it. In a tweet, on its official handle, the company said, “A new milestone…

[clevercase]

Shortage of vaccine raw materials, SII CEO to Biden: End export embargo

Shortage of vaccine raw materials, SII CEO to Biden: End export embargo

Serum Institute of India CEO Adar Poonawalla Friday urged US President Joe Biden to lift the embargo on export of raw materials needed to ramp up production of Covishield and Covovax, the Covid-19 vaccines it is making in India. In a Twitter post, tagging the US President, Poonawalla said: “Respected @POTUS, if we are to truly unite in beating this virus, on behalf of the vaccine industry outside…

[phgq]

PH enters into agreement for 30M COVID-19 vaccines

#PHinfo: PH enters into agreement for 30M COVID-19 vaccines

Caption: PH and SII signing of agreement. Photo grab from The Presidential Spokesperson's FB page

QUEZON CITY, Jan. 12 (PIA) -- The Philippine government through National Task Force Against COVID-10 Chief implementer and vaccine czar Secretary Carlito Galvez, Jr signed a term sheet agreement with the Serum Institute of India (SII) and Faberco Life Sciences, Inc. for 30 million doses of COVOVAX (NVX-CoV2373).

With this agreement, the Philippines can expect the delivery of the first doses of Covovax vaccine by the third quarter of 2021, said Presidential Spokesperson Secretary Harry Roque Jr. during a Palace briefing on January 11, 2021.

“Ang maganda po sa Covovax ay kinakailangan lamang ng 2 degrees Centigrade to 8 degrees Centigrade, ang standard temperature sa existing cold chain system sa Pilipinas,” said Roque. 

COVOVAX is the tradename for the research name NVX-CoV2373 developed by Novavax that partnered with SII. Novavax is a US-based biotechnology company with expertise in developing the next-generation vaccines for serious infectious diseases.

On the other hand, SII is the largest manufacturer of vaccines in the world, with most of its products being World Health Organization (WHO) prequalified. This implies a good track record on quality and good manufacturing practices, and a long track record with the Department of Health (DOH) in providing the Philippine government's Expanded Program for Immunization (EPI).

According to Dr. Ma. Luningning Elio-Villa, Medical Director/Chair, Advisory Board of Faberco Life Sciences Inc., guest during the Palace briefing said the signing of the partnership of the Philippine government and SII confirms the commitment of SII to deliver the COVID-19 vaccine COVOVAX in the Philippines.

“We are happy to share and confirm na ang term sheet ng pag-suplay ng 30 million doses of COVOVAX ay napirmahan na, [na] ibig sabihin nito ay magkakaroon ng commitment na magsusuplay ng 30 million doses ng COVOVAX ang Serum Institute sa Pilipinas (We are happy to share and confirm that the term sheet to supply 30 million doses of COVOVAX was already signed, which means that there is already a commitment to supply the 30 million doses by the Serum Institute in the Philippines)," Dr. Elio-Villa said.

Faberco has been authorized by the SII to represent the distributorship of COVOVAX in the Philippines. 

“Ang Faberco ang magiging coordinator to ensure that the vaccines are properly received dito sa Pilipinas at ma-coordinate ang pag-deliver sa ating national government” (Faberco will be the coordinator to ensure that the vaccines are properly received in the Philippines and delivered to our national government), Dr. Villa added.

Dr. Villa also said that for now, COVOVAX has no Emergency Used Authorization (EUA) yet. She said it will be the United Kingdom which will have the first EUA after being the first to finish the clinical trials. 

Based on the result of the Phase 3 clinical trial, Dr. Villa is optimistic to have an EUA for the vaccine here in the country through the Food and Drug Administration's (FDA) evaluation. (MBP/PIA-IDPD)

***

References:

* Philippine Information Agency. "PH enters into agreement for 30M COVID-19 vaccines." Philippine Information Agency. https://pia.gov.ph/news/articles/1063652 (accessed January 12, 2021 at 07:52PM UTC+08).

* Philippine Infornation Agency. "PH enters into agreement for 30M COVID-19 vaccines." Archive Today. https://archive.ph/?run=1&url=https://pia.gov.ph/news/articles/1063652 (archived).